Novartis wants U.K. to quash off-label Avastin use

Novartis ($NVS) is taking up arms against British eye doctors who use Roche's ($RHHBY) Avastin. Novartis markets Lucentis, a much pricier treatment for wet age-related macular degeneration. Lucent…
Read the full story: News